Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618 is registered in ClinicalTrials.gov with Shattuck Labs, Inc. as lead sponsor.

NCT NCT03894618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03894618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Lead sponsor
Shattuck Labs, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 26, 2019
Completion date
May 4, 2023
Enrollment
49 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hodgkin lymphoma, melanoma, mismatch repair deficient or msi-high solid tumors, non small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the anus, squamous cell carcinoma of the cervix, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the skin, urothelial carcinoma